***Background.*** We evaluated the activity of meropenem (MER) ± RPX7009 (RPX), a serine-β-lactamase inhibitor (BLI) tested against contemporary isolates of Enterobacteriaceae (ENT), including KPC-producing isolates.

***Methods.*** 100 ENT clinical isolates collected during 2012-2013 were tested against MER ± RPX at fixed 4 and 8 µg/mL using CLSI reference broth microdilution methods. Additionally, 100 KPC-producing ENT were tested.

***Results.*** Against all 200 ENT, MER/RPX displayed MIC~50/90~ of ≤0.25/1 and ≤0.25/0.5 µg/mL at fixed 4 and 8 µg/mL, respectively when compared to MIC~50/90~ ≤0.25/ \> 8 µg/ml for MER alone (Table). Overall, 91.5/95.5% and 96.0/99.0% of ENT were inhibited at ≤1/ ≤ 4 µg/mL of MER in the presence of 4 or 8 µg/ml of RPX, respectively. MER/RPX at fixed 4 and 8 µg/mL, inhibited 80.3 and 90.8%, respectively of the *K. pneumoniae* (n = 76) isolates at ≤1 µg/mL (MER CLSI susceptible breakpoint), whereas MER inhibited only 21.1% at the same MIC. Only 32.0% of *E. cloacae* isolates (n = 25) were inhibited at 1 µg/mL of MER, but 96.0% of these isolates were inhibited by MER/RPX (at the same MIC Value) for 4 and 8 µg/mL. All *E. coli* (n = 38), *Serratia* spp. (n = 12) and indole-positive Proteae (n = 11) isolates were inhibited by ≤0.25 µg/mL of MER/RPX at fixed 4 or 8 µg/mL. MER/RPX inhibited 83.0 and 91.0% and 92 and 98 % of the KPC-producers at ≤1 and ≤4 µg/mL of MER for both BLI concentrations, compared to only 3.0% or 24.0% for MER alone, respectively.

***Conclusion.*** These results demonstrate that MER/RPX is a good candidate for further development that could increase the treatment options against serious infections, including those caused by KPC-producers that are often resistant to most antimicrobial agents.

  Organism (no. tested)   Antimicrobial agent^a^   Cumulative % inhibited at MIC (µg/mL)^b^:                                           
  ----------------------- ------------------------ ------------------------------------------- ---------- ---------- ------ ---------- ----------
  ENT (200)               MER                      50.0                                        50.5       51.5       54.5   62.0       71.0
                          MER/RPX 4                87.0                                        89.0       **91.5**   94.0   96.0       98.0
                          MER/RPX 8                89.5                                        **92.5**   95.5       98.5   99.0       99.0
  *K. pneumoniae* (76)    MER                      19.7                                        21.1       21.1       22.4   25.0       36.8
                          MER/RPX 4                69.7                                        72.4       73.7       75.0   77.6       85.5
                          MER/RPX 8                72.4                                        75.0       80.3       85.5   89.5       **94.7**
  KPC-producers (100)     MER                      0.0                                         1.0        3.0        9.0    24.0       42.0
                          MER/RPX 4                74.0                                        78.0       83.0       88.0   **92.0**   96.0
                          MER/RPX 8                79.0                                        85.0       **91.0**   97.0   98.0       98.0

a\. MER/RPX=meropenem/RPX7009; 4=at fixed 4 µg/mL; 8=at fixed 4 µg/mL

b\. MIC~90~ are bolded
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